Format

Send to

Choose Destination
Clin Perinatol. 2015 Sep;42(3):469-81. doi: 10.1016/j.clp.2015.04.004. Epub 2015 May 14.

Erythropoietin and Neonatal Neuroprotection.

Author information

1
Division of Neonatology, Department of Pediatrics, University of Washington, 1959 Northeast Pacific Street, Box 356320, Seattle, WA 98195-6320, USA. Electronic address: sjuul@uw.edu.
2
Division of Neonatology, Department of Pediatrics, University of Washington, 1959 Northeast Pacific Street, Box 356320, Seattle, WA 98195-6320, USA.

Abstract

Certain groups of neonates are at high risk of developing long-term neurodevelopmental impairment and might be considered candidates for neuroprotective interventions. This article explores some of these high-risk groups, relevant mechanisms of brain injury, and specific mechanisms of cellular injury and death. The potential of erythropoietin (Epo) to act as a neuroprotective agent for neonatal brain injury is discussed. Clinical trials of Epo neuroprotection in preterm and term infants are updated.

KEYWORDS:

Apoptosis; Autophagy; Brain injury; Erythropoietin; Extreme prematurity; Hypoxic ischemic encephalopathy; Necrosis

PMID:
26250911
PMCID:
PMC4529536
DOI:
10.1016/j.clp.2015.04.004
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center